Identification

Name
Celecoxib
Accession Number
DB00482  (APRD00373)
Type
Small Molecule
Groups
Approved, Investigational
Description

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. Celecoxib is available by prescription in capsule form [7].

By inhibiting prostaglandin synthesis, non-steroidal anti-inflammatory drugs (NSAIDs) cause mucosal damage, ulceration and ulcer complication throughout the gastrointestinal tract. Celecoxib, however, poses less of an ulceration risk, owing to its decreased effect on gastric mucosal prostaglandin synthesis, when compared to placebo [8].

Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies [7].

Structure
Thumb
Synonyms
  • Celecoxib
  • Célécoxib
  • Celecoxibum
  • P-(5-P-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
External IDs
SC 58635 / YM 177
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act CelecoxibCapsule200 mgOralActavis Pharma Company2014-11-21Not applicableCanada
Act CelecoxibCapsule100 mgOralActavis Pharma Company2014-11-21Not applicableCanada
CelebrexCapsule200 mg/1OralProficient Rx LP1998-10-02Not applicableUs
CelebrexCapsule100 mg/1OralG.D. Searle LLC Division of Pfizer Inc1998-10-02Not applicableUs0025 152020180812 28838 i4l73u
CelebrexCapsule100 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-11-22Not applicableUs
CelebrexCapsule200 mgOralPfizer1999-04-19Not applicableCanada
CelebrexCapsule200 mg/1OralAidarex Pharmaceuticals LLC1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralPhysicians Total Care, Inc.1998-10-02Not applicableUs
CelebrexCapsule200 mg/1OralKeltman Pharmaceuticals Inc.2006-03-01Not applicableUs
CelebrexCapsule100 mg/1OralRebel Distributors1998-10-02Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-celecoxibCapsule200 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Accel-celecoxibCapsule100 mgOralAccel Pharma Inc2015-03-26Not applicableCanada
Ag-celecoxibCapsule200 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Ag-celecoxibCapsule100 mgOralAngita Pharma Inc.Not applicableNot applicableCanada
Apo-celecoxibCapsule100 mgOralApotex Corporation2014-11-17Not applicableCanada
Apo-celecoxibCapsule200 mgOralApotex Corporation2014-11-17Not applicableCanada
Auro-celecoxibCapsule200 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Auro-celecoxibCapsule100 mgOralAuro Pharma Inc2015-12-02Not applicableCanada
Bio-celecoxibCapsule200 mgOralBiomed Pharma2014-12-05Not applicableCanada
Bio-celecoxibCapsule100 mgOralBiomed Pharma2014-12-05Not applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
CapxibCelecoxib + Capsaicin + MentholKitOral; TopicalMas Management Group2015-06-032018-04-11Us
LidoXibCelecoxib + Lidocaine + MentholKitOralMas Management Group2015-06-032018-04-11Us
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (400 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (400 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
OnsenalCelecoxib (200 mg)CapsuleOralPfizer2003-10-172011-04-06Eu
International/Other Brands
Articox (Keyfarm) / Articoxib (Nabiqasim) / Artiflex (Standpharm) / Artilog (Pfizer) / Artix (Pharmalab) / Artrixib (Intipharma) / Blockten (Infarmasa) / Caditar (Farmindustria) / Cefinix (Farmacoop) / Celact (Sun) / Celebra (Pfizer) / Celebrex / Onsenal (Pfizer) / Valdyne (Pfizer)
Categories
UNII
JCX84Q7J1L
CAS number
169590-42-5
Weight
Average: 381.372
Monoisotopic: 381.075882012
Chemical Formula
C17H14F3N3O2S
InChI Key
RZEKVGVHFLEQIL-UHFFFAOYSA-N
InChI
InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)
IUPAC Name
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzene-1-sulfonamide
SMILES
CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F

Pharmacology

Indication

For the relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis [Label].

Associated Conditions
Pharmacodynamics

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). The inhibition of prostaglandin E2 synthesis which (a mediator of pain) results from the inhibition of COX-2, and helps to alleviate pain symptoms [Label].

Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Due to its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis [Label].

Mechanism of action

Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme [Label].

The mechanism of action of celecoxib is the inhibition of prostaglandin synthesis through COX-2 inhibition [Label].

COX-2 is expressed heavily in inflamed tissues where it is induced by inflammatory mediators. COX-2 also plays physiological roles in a limited number of tissues, including those of the female reproductive tract, the kidney, and possibly the vascular endothelium [13].

TargetActionsOrganism
AProstaglandin G/H synthase 2
inhibitor
Human
U3-phosphoinositide-dependent protein kinase 1
inhibitor
Human
UCarbonic anhydrase 2
inhibitor
Human
UCarbonic anhydrase 3
inhibitor
Human
UATP-binding cassette sub-family B member 5
substrate
Human
UATP-binding cassette sub-family G member 2Not AvailableHuman
UMultidrug resistance protein 1Not AvailableHuman
Absorption

Easily absorbed in the gastrointestinal tract. When a single dose of 200 mg is given to healthy subjects, peak plasma levels occur 3 hours after an oral dose. The peak plasma level is 705 ng/mL. Absolute bioavailability studies have not been conducted. When multiple doses are given, steady-state is reached on or before Day 5. When taken with a high-fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20% [Label].

A meta-analysis of pharmacokinetic studies has suggested an approximately 40% higher AUC (area under the curve) of celecoxib in black patients compared to Caucasians for unknown reasons [13].

Volume of distribution

The apparent volume of distribution at steady state (Vss/F) is about 400 L, suggesting extensive distribution into various tissues. Celecoxib is not preferentially bound to red blood cells [Label].

Protein binding

97%, primarily to albumin in healthy patients [Label].

Metabolism

Celecoxib metabolism is primarily mediated via cytochrome P450 2C9, in the liver. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors. Patients who are known or suspected to be P450 2C9 poor metabolizers, based on a previous history, should be administered celecoxib with caution as they may have abnormally high plasma levels due to their reduced metabolic clearance [Label].

When celecoxib capsules were taken with a high-fat meal, peak plasma levels were delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20% [Label].

Route of elimination

Celecoxib is eliminated predominantly by hepatic metabolism with little (<3%) unchanged drug recovered in the urine and feces. 57% of the oral dose is excreted in the feces and 27% is excreted into the urine. The primary metabolite in urine and feces was the carboxylic acid metabolite (73%). The amount of glucuronide in the urine is low [Label].

Half life

The effective half-life is approximately 11 hours when a single 200 mg dose is given to healthy subjects. Terminal half-life is generally variable because of the low solubility of the drug thus prolonging absorption [Label].

Clearance

Apparent clearance (CL/F), single oral 200 mg dose, healthy subjects = 27.7 L/hr [Label].

Toxicity

LD50 in both the rat and dog is >2000 mg/kg [Label].

It is not advisable to administer celecoxib in patients with renal impairment or advanced hepatic impairment [Label]. Symptoms of overdose celecoxib include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting [11]. Because serious GI tract ulcerations and bleeding can occur without preceding symptoms, physicians should monitor for signs/symptoms of GI bleeding [Label].

Multiple studies have been performed on the coadministration of celecoxib and proton pump inhibitors [9], [10]. It has been concluded that in patients at high risk of both cardiovascular and gastrointestinal events who require concomitant aspirin and NSAID, celecoxib in addition to a proton-pump inhibitor is the preferred treatment to reduce the risk of recurrent episodes of upper gastrointestinal bleeding [10].

A note on cardiovascular safety:

The concerns about the cardiovascular thrombotic risk of COX-2 selective NSAIDS emerged in the early 2000’s. Following an FDA Advisory Committee meeting in 2005, in which data from large clinical outcome trials in a wide range of indications and epidemiology studies of several individual NSAIDs were analyzed, the FDA concluded that the risk for cardiovascular thrombotic events was apparent for both COX-2 selective NSAIDs and nonselective NSAIDs [11].

Importantly, postmarketing cardiovascular outcomes trial (PRECISION) found that the lowest dose of celecoxib was similar to moderate doses of naproxen and ibuprofen in regards to cardiovascular (CV) safety [11]. Patients with recent cardiovascular events such as acute MI, coronary revascularization, or coronary stent placement were not studied in the PRECISION trial. NSAID use is not advisable in these groups of patients [11].

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Celecoxib Action PathwayDrug action
Celecoxib Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2C9CYP2C9*3(C;C) / (A;C)C AlleleEffect Directly StudiedPatients with this genotype have reduced metabolism of celecoxib.Details
Cytochrome P450 2C9CYP2C9*6Not Available818delAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*15Not Available485C>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*25Not Available353_362delAGAAATGGAAEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*35Not Available374G>T / 430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*2Not Available430C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*4Not Available1076T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*5Not Available1080C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*8Not Available449G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*11Not Available1003C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*12Not Available1465C>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*13Not Available269T>CEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*14Not Available374G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*16Not Available895A>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*18Not Available1075A>C / 1190A>C  … show all Effect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*26Not Available389C>GEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*28Not Available641A>TEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*30Not Available1429G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails
Cytochrome P450 2C9CYP2C9*33Not Available395G>AEffect InferredPoor drug metabolizer, lower dose requirementsDetails

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Celecoxib.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 19-norandrostenedione.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Celecoxib.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with 5-androstenedione.Experimental, Illicit
AbciximabCelecoxib may increase the anticoagulant activities of Abciximab.Approved
AbirateroneThe metabolism of Celecoxib can be decreased when combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Celecoxib.Approved, Investigational
AcebutololCelecoxib may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolCelecoxib may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetyl sulfisoxazoleThe metabolism of Celecoxib can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Celecoxib.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Celecoxib.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Celecoxib.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Celecoxib.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Celecoxib.Approved, Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Celecoxib.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Celecoxib.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.Approved
AliskirenCelecoxib may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Celecoxib.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Celecoxib.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Celecoxib.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Celecoxib.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Celecoxib.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideCelecoxib may decrease the antihypertensive activities of Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Celecoxib.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Celecoxib can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Celecoxib.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Celecoxib.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Celecoxib.Approved, Investigational
AmodiaquineThe metabolism of Amodiaquine can be decreased when combined with Celecoxib.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Celecoxib.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Celecoxib.Approved, Illicit, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Celecoxib.Approved, Investigational
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Celecoxib.Approved, Investigational
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Celecoxib.Approved, Investigational, Withdrawn
AncrodCelecoxib may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Celecoxib.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Celecoxib is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Celecoxib is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Celecoxib.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Antipyrine.Approved, Investigational
Antithrombin III humanCelecoxib may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Celecoxib can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanCelecoxib may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Celecoxib.Investigational
ApramycinCelecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Celecoxib.Approved, Investigational
AprepitantThe serum concentration of Celecoxib can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Celecoxib.Approved
ArbekacinCelecoxib may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinCelecoxib may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Celecoxib.Approved, Investigational
ArgatrobanCelecoxib may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
ArotinololCelecoxib may decrease the antihypertensive activities of Arotinolol.Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Celecoxib.Approved
AsenapineCelecoxib may decrease the antihypertensive activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Celecoxib.Approved, Withdrawn
AsunaprevirThe metabolism of Asunaprevir can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Atamestane.Investigational
AtazanavirThe metabolism of Celecoxib can be decreased when combined with Atazanavir.Approved, Investigational
AtenololCelecoxib may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Celecoxib can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe metabolism of Atorvastatin can be decreased when combined with Celecoxib.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Celecoxib.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Celecoxib.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Celecoxib.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Celecoxib.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Balsalazide.Approved, Investigational
BazedoxifeneCelecoxib may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BecaplerminCelecoxib may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Celecoxib.Approved, Investigational
BefunololCelecoxib may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinCelecoxib may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Celecoxib.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Celecoxib.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Celecoxib.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Celecoxib.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Celecoxib.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Celecoxib.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Celecoxib.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Celecoxib.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Betamethasone.Approved, Vet Approved
BetaxololThe metabolism of Betaxolol can be decreased when combined with Celecoxib.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Celecoxib.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
BevantololCelecoxib may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Celecoxib.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Celecoxib.Approved
BivalirudinCelecoxib may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Celecoxib can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololCelecoxib may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Celecoxib can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Celecoxib can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Celecoxib.Approved, Investigational
BrigatinibThe metabolism of Brigatinib can be decreased when combined with Celecoxib.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Celecoxib.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Celecoxib.Investigational
BucindololCelecoxib may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Celecoxib.Approved
BufexamacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Bufexamac.Approved, Experimental
BufuralolThe metabolism of Bufuralol can be decreased when combined with Celecoxib.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Celecoxib.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Celecoxib.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Celecoxib.Approved, Investigational
BupranololCelecoxib may decrease the antihypertensive activities of Bupranolol.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Celecoxib.Approved, Illicit, Investigational, Vet Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Celecoxib.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Celecoxib.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Celecoxib.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Celecoxib.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Candoxatril.Experimental
CapecitabineThe metabolism of Celecoxib can be decreased when combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Capsaicin.Approved
CaptoprilThe metabolism of Captopril can be decreased when combined with Celecoxib.Approved
CarbamazepineThe metabolism of Celecoxib can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Celecoxib.Experimental, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Celecoxib.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Celecoxib.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Celecoxib.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Celecoxib.Approved
CarvedilolCelecoxib may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Celecoxib.Experimental
CeliprololCelecoxib may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Celecoxib can be increased when it is combined with Ceritinib.Approved
CerivastatinThe metabolism of Cerivastatin can be decreased when combined with Celecoxib.Approved, Withdrawn
CertoparinCelecoxib may increase the anticoagulant activities of Certoparin.Approved, Investigational
CevimelineThe metabolism of Cevimeline can be decreased when combined with Celecoxib.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Celecoxib.Approved, Illicit, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Celecoxib.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
ChlorotrianiseneCelecoxib may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenesinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Celecoxib.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Celecoxib.Approved
CholecalciferolThe metabolism of Celecoxib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cilazapril.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Celecoxib.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cimicoxib.Investigational
CinoxacinCelecoxib may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinCelecoxib may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
CisplatinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cisplatin.Approved
CitalopramCitalopram may increase the antiplatelet activities of Celecoxib.Approved
ClarithromycinThe metabolism of Celecoxib can be decreased when combined with Clarithromycin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Celecoxib.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Celecoxib.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Celecoxib.Vet Approved
CloranololCelecoxib may decrease the antihypertensive activities of Cloranolol.Experimental
ClorindioneCelecoxib may increase the anticoagulant activities of Clorindione.Experimental
ClotrimazoleThe metabolism of Celecoxib can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Celecoxib.Approved
CobicistatThe metabolism of Celecoxib can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Celecoxib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Celecoxib.Approved, Investigational
Conjugated estrogensCelecoxib may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Cortisone acetate.Approved, Investigational
CrisaboroleThe metabolism of Celecoxib can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibThe metabolism of Celecoxib can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Celecoxib.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Celecoxib.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Celecoxib is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Celecoxib.Experimental
Dabigatran etexilateCelecoxib may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Celecoxib can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinCelecoxib may increase the thrombogenic activities of Daidzein.Experimental
DalteparinCelecoxib may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidCelecoxib may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Celecoxib.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Celecoxib.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Celecoxib.Approved, Investigational
DarexabanCelecoxib may increase the anticoagulant activities of Darexaban.Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Celecoxib.Approved, Investigational
DarunavirThe metabolism of Celecoxib can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Celecoxib.Approved
DasatinibThe serum concentration of Celecoxib can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Celecoxib.Approved, Investigational
DeferasiroxThe serum concentration of Celecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Celecoxib is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Delapril.Investigational
DelavirdineThe metabolism of Celecoxib can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Celecoxib.Approved, Investigational
DesirudinCelecoxib may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Celecoxib.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Desvenlafaxine is combined with Celecoxib.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Celecoxib.Approved, Investigational
DexamethasoneThe serum concentration of Celecoxib can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Dexamethasone isonicotinate.Vet Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Celecoxib.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Celecoxib.Approved, Illicit, Investigational, Withdrawn
DexibuprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Celecoxib.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Celecoxib.Experimental
DextranCelecoxib may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Celecoxib.Approved, Illicit
DiazepamThe metabolism of Diazepam can be decreased when combined with Celecoxib.Approved, Illicit, Investigational, Vet Approved
DibekacinCelecoxib may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Celecoxib is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Celecoxib.Approved, Vet Approved
DicoumarolCelecoxib may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolCelecoxib may increase the thrombogenic activities of Dienestrol.Approved, Investigational
DiethylstilbestrolCelecoxib may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Celecoxib.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Celecoxib is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Celecoxib.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Celecoxib.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Celecoxib.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Celecoxib.Approved, Illicit
DihydroergotamineThe metabolism of Celecoxib can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydrostreptomycinCelecoxib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Celecoxib can be decreased when combined with Diltiazem.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Celecoxib.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Celecoxib.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Celecoxib.Approved
DiphenadioneCelecoxib may increase the anticoagulant activities of Diphenadione.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Celecoxib.Approved, Investigational
DomperidoneThe metabolism of Domperidone can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Celecoxib.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Celecoxib.Approved
DosulepinThe metabolism of Celecoxib can be decreased when combined with Dosulepin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Celecoxib.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Celecoxib.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Celecoxib.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Celecoxib.Approved, Investigational
DoxycyclineThe metabolism of Celecoxib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Celecoxib can be decreased when combined with Dronedarone.Approved
DrospirenoneCelecoxib may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Droxicam.Withdrawn
DuloxetineDuloxetine may increase the antiplatelet activities of Celecoxib.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Celecoxib.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Celecoxib.Investigational
Edetic AcidCelecoxib may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanCelecoxib may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe metabolism of Celecoxib can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Celecoxib.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Celecoxib.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Celecoxib.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Celecoxib is combined with Enalaprilat.Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Celecoxib.Approved, Investigational
EncainideThe metabolism of Encainide can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Celecoxib.Investigational
EnoxacinCelecoxib may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinCelecoxib may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Celecoxib.Experimental
EnzalutamideThe serum concentration of Celecoxib can be decreased when it is combined with Enzalutamide.Approved
EpanololCelecoxib may decrease the antihypertensive activities of Epanolol.Experimental
EpimestrolCelecoxib may increase the thrombogenic activities of Epimestrol.Experimental
EpinastineThe metabolism of Epinastine can be decreased when combined with Celecoxib.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Celecoxib.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Celecoxib.Experimental
EplerenoneCelecoxib may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Celecoxib.Approved
EquileninThe risk or severity of adverse effects can be increased when Celecoxib is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Equilin.Approved
EquolCelecoxib may increase the thrombogenic activities of Equol.Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Celecoxib.Approved, Investigational
ErythromycinThe metabolism of Celecoxib can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EsatenololCelecoxib may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Celecoxib.Investigational
EsmololCelecoxib may decrease the antihypertensive activities of Esmolol.Approved
EstradiolCelecoxib may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetateCelecoxib may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
Estradiol cypionateCelecoxib may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
Estradiol valerateCelecoxib may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolCelecoxib may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedCelecoxib may increase the thrombogenic activities of Estrogens, esterified.Approved
EstroneCelecoxib may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Estrone sulfate.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Celecoxib.Approved, Investigational
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Celecoxib.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Celecoxib.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Celecoxib.Experimental
Ethinyl EstradiolCelecoxib may increase the thrombogenic activities of Ethinyl Estradiol.Approved
Ethyl biscoumacetateCelecoxib may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Celecoxib.Approved, Illicit
Etidronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Celecoxib.Approved, Investigational
EtoperidoneEtoperidone may increase the antiplatelet activities of Celecoxib.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Celecoxib can be decreased when combined with Etravirine.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Celecoxib.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Celecoxib.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Celecoxib.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Celecoxib.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Celecoxib.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Celecoxib.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Celecoxib.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Celecoxib.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Celecoxib.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Celecoxib.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Celecoxib.Approved, Investigational
FingolimodThe metabolism of Fingolimod can be decreased when combined with Celecoxib.Approved, Investigational
FlecainideThe metabolism of Flecainide can be decreased when combined with Celecoxib.Approved, Withdrawn
FleroxacinCelecoxib may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Celecoxib.Approved, Withdrawn
FloxuridineThe metabolism of Celecoxib can be decreased when combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Celecoxib can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fludrocortisone.Approved, Investigational
FluindioneCelecoxib may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineCelecoxib may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Celecoxib.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Celecoxib.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Celecoxib.Approved, Investigational
FluorouracilThe metabolism of Celecoxib can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluoxetine is combined with Celecoxib.Approved, Vet Approved
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Celecoxib.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Celecoxib.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Celecoxib.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Celecoxib.Approved
FluvoxamineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Fluvoxamine is combined with Celecoxib.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Celecoxib.Approved, Nutraceutical, Vet Approved
FondaparinuxCelecoxib may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Celecoxib.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolThe metabolism of Formoterol can be decreased when combined with Celecoxib.Approved, Investigational
FosamprenavirThe metabolism of Celecoxib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Celecoxib can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Celecoxib can be increased when combined with Fosphenytoin.Approved, Investigational
FramycetinCelecoxib may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
Fusidic AcidThe serum concentration of Celecoxib can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabexateCelecoxib may increase the anticoagulant activities of Gabexate.Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Celecoxib.Approved
GarenoxacinCelecoxib may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinCelecoxib may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Celecoxib.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Celecoxib.Approved, Withdrawn
GemfibrozilThe metabolism of Celecoxib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinCelecoxib may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinCelecoxib may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinCelecoxib may increase the thrombogenic activities of Genistein.Investigational
GentamicinCelecoxib may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1ACelecoxib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Celecoxib.Experimental
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Celecoxib.Approved
GlipizideThe protein binding of Glipizide can be decreased when combined with Celecoxib.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Celecoxib.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Celecoxib.Approved, Investigational
GrepafloxacinCelecoxib may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Celecoxib.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Celecoxib.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Halcinonide.Approved, Investigational, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Celecoxib.Approved
HaloperidolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Celecoxib.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when Celecoxib is combined with HE3286.Investigational
HeparinCelecoxib may increase the anticoagulant activities of Heparin.Approved, Investigational
HexestrolCelecoxib may increase the thrombogenic activities of Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Celecoxib.Investigational
HydralazineCelecoxib may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
HydrocodoneThe serum concentration of the active metabolites of Hydrocodone can be reduced when Hydrocodone is used in combination with Celecoxib resulting in a loss in efficacy.Approved, Illicit
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Celecoxib.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Celecoxib.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Celecoxib.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Celecoxib.Approved, Illicit
Hygromycin BCelecoxib may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Ibandronate.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Celecoxib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Celecoxib.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Celecoxib.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Celecoxib is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Celecoxib.Approved
IdelalisibThe metabolism of Celecoxib can be decreased when combined with Idelalisib.Approved
IdraparinuxCelecoxib may increase the anticoagulant activities of Idraparinux.Investigational
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Celecoxib.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Celecoxib.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.Approved, Investigational
ImatinibThe metabolism of Celecoxib can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Celecoxib.Experimental
ImipramineThe metabolism of Imipramine can be decreased when combined with Celecoxib.Approved
IndalpineIndalpine may increase the antiplatelet activities of Celecoxib.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Celecoxib.Approved
IndenololCelecoxib may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Celecoxib can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Celecoxib.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Celecoxib.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Celecoxib.Withdrawn
IpecacThe metabolism of Ipecac can be decreased when combined with Celecoxib.Approved, Withdrawn
IrbesartanThe metabolism of Celecoxib can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Celecoxib can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Celecoxib can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinCelecoxib may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Celecoxib.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Celecoxib.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Celecoxib is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Celecoxib can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Celecoxib can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Celecoxib.Approved, Investigational
KanamycinCelecoxib may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Celecoxib.Experimental
KetamineThe metabolism of Ketamine can be decreased when combined with Celecoxib.Approved, Vet Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Celecoxib.Approved, Investigational
KetoconazoleThe metabolism of Celecoxib can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Celecoxib.Approved
LabetalolCelecoxib may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Celecoxib.Experimental
LandiololCelecoxib may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe metabolism of Lansoprazole can be decreased when combined with Celecoxib.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Celecoxib.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Celecoxib.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Celecoxib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Celecoxib.Approved, Investigational
LepirudinCelecoxib may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
LetaxabanCelecoxib may increase the anticoagulant activities of Letaxaban.Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Celecoxib.Approved, Investigational
LevobetaxololCelecoxib may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololCelecoxib may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinCelecoxib may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Celecoxib.Approved, Investigational
LicofeloneThe metabolism of Licofelone can be decreased when combined with Celecoxib.Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Celecoxib.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Celecoxib.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Celecoxib.Approved, Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Celecoxib.Experimental
LobeglitazoneThe metabolism of Celecoxib can be decreased when combined with Lobeglitazone.Approved, Investigational
LofexidineThe metabolism of Lofexidine can be decreased when combined with Celecoxib.Approved, Investigational
LomefloxacinCelecoxib may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LomustineThe metabolism of Lomustine can be decreased when combined with Celecoxib.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Celecoxib.Experimental
LopinavirThe metabolism of Celecoxib can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Celecoxib.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Celecoxib can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Celecoxib.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Loteprednol.Approved
LovastatinThe metabolism of Celecoxib can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Celecoxib.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Celecoxib.Approved, Investigational
LuliconazoleThe serum concentration of Celecoxib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Celecoxib can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Celecoxib.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Celecoxib.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Celecoxib.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Celecoxib.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Celecoxib is combined with ME-609.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mefenamic acid.Approved
MelagatranCelecoxib may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Meloxicam.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Celecoxib.Investigational, Withdrawn
MepindololCelecoxib may decrease the antihypertensive activities of Mepindolol.Experimental
MequitazineThe metabolism of Mequitazine can be decreased when combined with Celecoxib.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Celecoxib.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Celecoxib.Approved, Investigational
MestranolCelecoxib may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Celecoxib.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Celecoxib.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Celecoxib.Approved
MethallenestrilCelecoxib may increase the thrombogenic activities of Methallenestril.Experimental
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Celecoxib.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Celecoxib.Approved
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Celecoxib.Approved, Investigational
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Celecoxib.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Celecoxib.Approved, Vet Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Celecoxib.Approved, Illicit, Withdrawn
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Celecoxib.Experimental
MetipranololCelecoxib may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Celecoxib.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Celecoxib.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Celecoxib.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Celecoxib.Approved, Investigational
MibefradilThe metabolism of Celecoxib can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Celecoxib can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MicronomicinCelecoxib may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidostaurinThe metabolism of Celecoxib can be decreased when combined with Midostaurin.Approved, Investigational
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Celecoxib.Approved, Experimental
MifepristoneThe serum concentration of Celecoxib can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the antiplatelet activities of Celecoxib.Approved, Investigational
MinaprineThe metabolism of Minaprine can be decreased when combined with Celecoxib.Approved
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Celecoxib.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Celecoxib.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Celecoxib.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Celecoxib.Approved
MitotaneThe serum concentration of Celecoxib can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Celecoxib.Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Celecoxib.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Celecoxib.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Celecoxib.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Celecoxib.Approved, Investigational
MoxestrolCelecoxib may increase the thrombogenic activities of Moxestrol.Experimental
MoxifloxacinCelecoxib may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MuraglitazarThe metabolism of Muraglitazar can be decreased when combined with Celecoxib.Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Celecoxib.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Celecoxib.Approved
NabiloneThe metabolism of Celecoxib can be decreased when combined with Nabilone.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Celecoxib.Approved
NadololCelecoxib may decrease the antihypertensive activities of Nadolol.Approved
NadroparinCelecoxib may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Celecoxib.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Celecoxib.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Celecoxib.Investigational
Nalidixic AcidCelecoxib may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaloxoneThe metabolism of Naloxone can be decreased when combined with Celecoxib.Approved, Vet Approved
NaproxenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Naproxen.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Celecoxib.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Celecoxib is combined with NCX 1022.Investigational
NeamineCelecoxib may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Celecoxib.Approved, Investigational
NefazodoneThe metabolism of Celecoxib can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Celecoxib can be decreased when combined with Nelfinavir.Approved
NemonoxacinCelecoxib may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Celecoxib.Approved, Investigational
NetilmicinCelecoxib may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Celecoxib can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Celecoxib can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Celecoxib can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Celecoxib.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nicotine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Celecoxib.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Celecoxib.Experimental
NilotinibThe metabolism of Celecoxib can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Celecoxib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Celecoxib.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Celecoxib.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Celecoxib.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Celecoxib.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Celecoxib.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
Nitrous acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Nitrous acid.Approved, Investigational
NorfloxacinCelecoxib may increase the neuroexcitatory activities of Norfloxacin.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Celecoxib.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Celecoxib.Investigational
OfloxacinCelecoxib may increase the neuroexcitatory activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Celecoxib.Approved, Investigational
OlaparibThe metabolism of Celecoxib can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Celecoxib.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Celecoxib.Approved, Investigational
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Celecoxib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Celecoxib.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Celecoxib.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Celecoxib is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Celecoxib is combined with Omapatrilat.Investigational
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Celecoxib.Approved, Investigational
OpiumThe metabolism of Opium can be decreased when combined with Celecoxib.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Celecoxib.Vet Approved
OsimertinibThe serum concentration of Celecoxib can be increased when it is combined with Osimertinib.Approved
OtamixabanCelecoxib may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Celecoxib.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Oxaprozin.Approved
Oxolinic acidCelecoxib may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololCelecoxib may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Celecoxib.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Celecoxib.Approved, Vet Approved
PalbociclibThe serum concentration of Celecoxib can be increased when it is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Celecoxib.Experimental, Nutraceutical
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Celecoxib.Approved, Investigational
PamidronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pamidronate.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Celecoxib.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Celecoxib is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Paroxetine is combined with Celecoxib.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Celecoxib.Approved, Investigational
PazopanibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.Approved
PazufloxacinCelecoxib may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinCelecoxib may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololCelecoxib may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateCelecoxib may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Celecoxib.Approved, Investigational
PentobarbitalThe metabolism of Celecoxib can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
Pentosan PolysulfateCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Celecoxib.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Celecoxib.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Celecoxib.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Celecoxib.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Celecoxib.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
PhenindioneCelecoxib may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Celecoxib can be increased when combined with Phenobarbital.Approved, Investigational
PhenprocoumonCelecoxib may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Celecoxib can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Celecoxib.Approved, Investigational
PindololThe metabolism of Pindolol can be decreased when combined with Celecoxib.Approved, Investigational
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Celecoxib.Approved, Investigational
Pipemidic acidCelecoxib may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiperazineThe metabolism of Piperazine can be decreased when combined with Celecoxib.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Celecoxib.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Celecoxib.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Celecoxib.Approved, Investigational
Piromidic acidCelecoxib may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Celecoxib is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Celecoxib.Experimental
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Celecoxib.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Celecoxib.Approved, Investigational
Platelet Activating FactorCelecoxib may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinCelecoxib may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
Polyestradiol phosphateCelecoxib may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Celecoxib.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Celecoxib.Approved, Investigational
PosaconazoleThe metabolism of Celecoxib can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium CitrateCelecoxib may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololCelecoxib may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Celecoxib.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Celecoxib.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Celecoxib.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pregnenolone.Approved, Experimental, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Prilocaine.Approved
PrimidoneThe metabolism of Celecoxib can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Celecoxib can be increased when it is combined with Probenecid.Approved, Investigational
ProcainamideThe metabolism of Procainamide can be decreased when combined with Celecoxib.Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Celecoxib.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Celecoxib.Experimental
PromestrieneCelecoxib may increase the thrombogenic activities of Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Celecoxib.Approved, Investigational
PropafenoneCelecoxib may decrease the antihypertensive activities of Propafenone.Approved
PropofolThe metabolism of Propofol can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
PropranololCelecoxib may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Celecoxib.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Celecoxib.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Celecoxib.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Celecoxib.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Celecoxib.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Celecoxib.Vet Approved
Protein CCelecoxib may increase the anticoagulant activities of Protein C.Approved
Protein S humanCelecoxib may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeCelecoxib may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Celecoxib.Approved
PrulifloxacinCelecoxib may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Celecoxib.Investigational
PuromycinCelecoxib may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
PyrimethamineThe metabolism of Celecoxib can be decreased when combined with Pyrimethamine.Approved, Investigational, Vet Approved
QuinaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Quinapril.Approved, Investigational
QuinestrolCelecoxib may increase the thrombogenic activities of Quinestrol.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Celecoxib.Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Celecoxib.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Celecoxib.Approved
RamiprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ramipril.Approved
RanolazineThe metabolism of Celecoxib can be decreased when combined with Ranolazine.Approved, Investigational
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Celecoxib.Approved, Withdrawn
RepaglinideThe metabolism of Repaglinide can be decreased when combined with Celecoxib.Approved, Investigational
RepinotanThe metabolism of Repinotan can be decreased when combined with Celecoxib.Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinCelecoxib may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinCelecoxib may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Celecoxib can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Celecoxib can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Celecoxib can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rimexolone.Approved
RiociguatThe metabolism of Riociguat can be decreased when combined with Celecoxib.Approved
RisedronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Celecoxib.Approved, Investigational
RitonavirThe metabolism of Ritonavir can be decreased when combined with Celecoxib.Approved, Investigational
RivaroxabanCelecoxib may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Rofecoxib.Approved, Investigational, Withdrawn
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Celecoxib.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Celecoxib.Approved, Investigational
RosoxacinCelecoxib may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RotigotineThe metabolism of Rotigotine can be decreased when combined with Celecoxib.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Celecoxib.Approved, Investigational
RufloxacinCelecoxib may increase the neuroexcitatory activities of Rufloxacin.Experimental
RupatadineThe metabolism of Rupatadine can be decreased when combined with Celecoxib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Celecoxib.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Celecoxib.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Celecoxib.Experimental
SaquinavirThe metabolism of Celecoxib can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Celecoxib.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Celecoxib.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Celecoxib.Approved
SecobarbitalThe metabolism of Celecoxib can be increased when combined with Secobarbital.Approved, Vet Approved
SecoisolariciresinolCelecoxib may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SelegilineThe metabolism of Selegiline can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
SelexipagThe metabolism of Selexipag can be decreased when combined with Celecoxib.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Celecoxib.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Celecoxib.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Celecoxib.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
SertralineSertraline may increase the antiplatelet activities of Celecoxib.Approved
SildenafilThe metabolism of Celecoxib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Celecoxib can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Celecoxib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Celecoxib.Approved
SisomicinCelecoxib may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinCelecoxib may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Celecoxib.Approved, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Celecoxib.Approved
SorafenibThe metabolism of Celecoxib can be decreased when combined with Sorafenib.Approved, Investigational
SotalolCelecoxib may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinCelecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SparteineThe metabolism of Sparteine can be decreased when combined with Celecoxib.Experimental
SpiraprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Celecoxib.Investigational
St. John's WortThe serum concentration of Celecoxib can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Celecoxib can be increased when it is combined with Stiripentol.Approved
StreptomycinCelecoxib may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfadiazineThe metabolism of Celecoxib can be decreased when combined with Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sulfasalazine.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Celecoxib.Approved
SulfisoxazoleThe metabolism of Celecoxib can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Celecoxib is combined with Sulindac.Approved, Investigational
SulodexideCelecoxib may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Celecoxib.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Celecoxib is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Celecoxib.Experimental
Synthetic Conjugated Estrogens, ACelecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BCelecoxib may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusCelecoxib may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Celecoxib.Approved
TalinololCelecoxib may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Celecoxib.Approved
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Celecoxib resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Celecoxib.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Celecoxib.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Celecoxib.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Celecoxib.Approved
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Celecoxib.Approved, Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Technetium Tc-99m medronate.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Celecoxib.Approved, Investigational, Withdrawn
TelaprevirThe metabolism of Celecoxib can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Celecoxib can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Celecoxib.Approved, Investigational
TemafloxacinCelecoxib may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemazepamThe metabolism of Temazepam can be decreased when combined with Celecoxib.Approved, Investigational
TemocaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Celecoxib.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Celecoxib.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Celecoxib.Vet Approved
TerbutalineCelecoxib may decrease the antihypertensive activities of Terbutaline.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Celecoxib.Approved, Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Celecoxib.Approved
TertatololCelecoxib may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Celecoxib.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Celecoxib.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Celecoxib.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Celecoxib.Approved
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Celecoxib.Approved, Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Celecoxib.Approved, Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Celecoxib.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Celecoxib.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Celecoxib.Approved, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiaprofenic acid.Approved
TiboloneCelecoxib may increase the thrombogenic activities of Tibolone.Approved, Investigational
TicagrelorThe metabolism of Celecoxib can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Celecoxib can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Celecoxib.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Celecoxib.Investigational
TioclomarolCelecoxib may increase the anticoagulant activities of Tioclomarol.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Celecoxib.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Celecoxib.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tixocortol.Approved, Withdrawn
TobramycinCelecoxib may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Celecoxib can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Celecoxib can be decreased when combined with Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Celecoxib is combined with Tolmetin.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Celecoxib.Approved, Investigational
TopiroxostatThe metabolism of Celecoxib can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Celecoxib.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Celecoxib.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Celecoxib.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Celecoxib.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Celecoxib.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Celecoxib.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Celecoxib.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Celecoxib is combined with Triamcinolone.Approved, Vet Approved
TriamtereneCelecoxib may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Celecoxib.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Celecoxib.Approved, Vet Approved
TrimethoprimThe metabolism of Celecoxib can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Celecoxib.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Celecoxib.Investigational
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Celecoxib.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trolamine salicylate.Approved
TrovafloxacinCelecoxib may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinCelecoxib may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Celecoxib is combined with Ulobetasol.Approved
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Celecoxib.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Celecoxib.Approved, Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Celecoxib.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Valdecoxib.Approved, Investigational, Withdrawn
Valproic AcidThe metabolism of Celecoxib can be decreased when combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Celecoxib can be decreased when combined with Valsartan.Approved, Investigational
VancomycinCelecoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Celecoxib.Approved, Investigational
VemurafenibThe serum concentration of Celecoxib can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Venlafaxine is combined with Celecoxib.Approved
VerapamilThe metabolism of Celecoxib can be decreased when combined with Verapamil.Approved
VernakalantThe metabolism of Vernakalant can be decreased when combined with Celecoxib.Approved, Investigational
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Celecoxib.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Celecoxib.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Celecoxib.Approved, Investigational
VoriconazoleThe metabolism of Celecoxib can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Celecoxib.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Celecoxib.Approved, Investigational
WarfarinCelecoxib may increase the anticoagulant activities of Warfarin.Approved
XimelagatranCelecoxib may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
YohimbineThe metabolism of Yohimbine can be decreased when combined with Celecoxib.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Celecoxib can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Celecoxib.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Celecoxib.Approved, Investigational
ZeranolCelecoxib may increase the thrombogenic activities of Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Celecoxib.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the antiplatelet activities of Celecoxib.Withdrawn
ZiprasidoneThe metabolism of Celecoxib can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Celecoxib is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Celecoxib is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Celecoxib.Withdrawn
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Celecoxib.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Celecoxib.Approved, Investigational
Food Interactions
  • Take without regard to meals.
  • Taking this product with a high-fat meal will delay the Cmax, but total absorption will be increased by 10 to 20%.

References

Synthesis Reference
US5466823
General References
  1. Malhotra S, Shafiq N, Pandhi P: COX-2 inhibitors: a CLASS act or Just VIGORously promoted. MedGenMed. 2004 Mar 23;6(1):6. [PubMed:15208519]
  2. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000 Sep 13;284(10):1247-55. [PubMed:10979111]
  3. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005 Mar 17;352(11):1071-80. Epub 2005 Feb 15. [PubMed:15713944]
  4. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 2007 Jan;46(1):135-40. Epub 2006 Jun 15. [PubMed:16777855]
  5. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84. [PubMed:16943400]
  6. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E: Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol. 2002 Oct;54(4):423-9. [PubMed:12392591]
  7. Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE: Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. [PubMed:22336956]
  8. Hawkey CJ: COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):801-20. doi: 10.1053/bega.2001.0236. [PubMed:11566042]
  9. Gwee KA, Goh V, Lima G, Setia S: Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018 Feb 14;11:361-374. doi: 10.2147/JPR.S156938. eCollection 2018. [PubMed:29491719]
  10. Chan FKL, Ching JYL, Tse YK, Lam K, Wong GLH, Ng SC, Lee V, Au KWL, Cheong PK, Suen BY, Chan H, Kee KM, Lo A, Wong VWS, Wu JCY, Kyaw MH: Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. Lancet. 2017 Jun 17;389(10087):2375-2382. doi: 10.1016/S0140-6736(17)30981-9. Epub 2017 Apr 11. [PubMed:28410791]
  11. FDA drug safety, June 28 2018 [Link]
  12. Medscape drug reference [Link]
  13. Pfizer Medical Information [Link]
External Links
Human Metabolome Database
HMDB0005014
KEGG Drug
D00567
KEGG Compound
C07589
PubChem Compound
2662
PubChem Substance
46505596
ChemSpider
2562
BindingDB
11639
ChEBI
41423
ChEMBL
CHEMBL118
Therapeutic Targets Database
DAP000737
PharmGKB
PA448871
HET
CEL
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Celecoxib
ATC Codes
L01XX33 — CelecoxibM01AH01 — CelecoxibG01AE10 — Combinations of sulfonamides
AHFS Codes
  • 28:08.04.08 — Cyclooxygenase-2 (COX-2) Inhibitors
PDB Entries
1oq5 / 3kk6 / 3ln1 / 4fim / 5jw1
FDA label
Download (174 KB)
MSDS
Download (51.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentStage IA Breast Cancer / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
0CompletedBasic ScienceBMI >30 kg/m21
0RecruitingBasic ScienceMajor Depressive Disorder (MDD)1
0RecruitingPreventionHealthy Volunteers1
0RecruitingTreatmentMetastatic Carcinoma in the Liver / Recurrent Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
0TerminatedBasic ScienceBone Ingrowth / Pain1
1Active Not RecruitingTreatmentGlioblastomas1
1Active Not RecruitingTreatmentNeuroblastomas1
1CompletedNot AvailableAutonomic Failure / Idiopathic orthostatic hypotension1
1CompletedNot AvailableHealthy Volunteers2
1CompletedBasic ScienceHealthy Volunteers7
1CompletedOtherMigraines1
1CompletedPreventionColorectal Cancers / Precancerous Conditions1
1CompletedPreventionHead and Neck Carcinoma1
1CompletedPreventionProstate Cancer1
1CompletedTreatmentAdvanced Esophageal Cancers / Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Lung Cancer Non-Small Cell Cancer (NSCLC) / Pleural Mesotheliomas / Primary Small Cell Lung Cancers1
1CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
1CompletedTreatmentColorectal Cancers / Diarrhea1
1CompletedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1CompletedTreatmentEsophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Sarcomas / Thymic Carcinoma1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentHereditary Nonpolyposis / Neoplasms, Colorectal1
1CompletedTreatmentLung Cancers3
1CompletedTreatmentNeoplasms, Hepatic1
1CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentPain1
1CompletedTreatmentPostoperative pain1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentStage I Breast Carcinoma / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
1CompletedTreatmentTuberculosis1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific3
1CompletedTreatmentPainful musculoskeletal conditions1
1RecruitingBasic ScienceElectrophysiologic Property of Brain1
1RecruitingOtherHealthy Volunteers1
1RecruitingTreatmentBladder Cancers1
1RecruitingTreatmentGliomas1
1TerminatedBasic ScienceHealthy Volunteers1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentEpithelial Malignancies / Melanoma / Pleural Malignancy / Sarcomas1
1TerminatedTreatmentAdvanced thymic carcinoma / Esophageal Cancers / Lung Cancers / Mesolthelioma / Thoracic Sarcomas1
1TerminatedTreatmentHealthy Volunteers1
1TerminatedTreatmentInflammatory Reaction1
1TerminatedTreatmentMalignant Neoplasm of Pancreas1
1Unknown StatusNot AvailableHealthy Male Volunteers1
1WithdrawnBasic ScienceLung Cancer Non-Small Cell Cancer (NSCLC)1
1WithdrawnTreatmentMelanoma / Neoplasms Metastasis / Neoplasms, Germ Cell and Embryonal / Sarcomas1
1, 2Active Not RecruitingTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
1, 2CompletedBasic ScienceCardiovascular Disease (CVD) / High Blood Pressure (Hypertension) / Obstructive Sleep Apnea (OSA) / Strokes1
1, 2CompletedBasic ScienceMouth Neoplasms1
1, 2CompletedPreventionBiomarker Change Linked to Breast Cancer1
1, 2CompletedPreventionCancer, Breast1
1, 2CompletedPreventionTobacco Use Disorders1
1, 2CompletedTreatmentAdvanced Melanoma1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCervical Cancers1
1, 2CompletedTreatmentCervix Neoplasms1
1, 2CompletedTreatmentLiver Cancer1
1, 2CompletedTreatmentLung Cancers2
1, 2CompletedTreatmentNasopharyngeal Carcinoma1
1, 2CompletedTreatmentNeoplasms, Colorectal1
1, 2RecruitingTreatmentMalignant Neoplasm of Pancreas Metastatic to Peritoneal Surface / Malignant Peritoneal Mesothelioma / Peritoneal Carcinomatosis1
1, 2SuspendedTreatmentCancers of Non-thoracic Origin With Metastases to the Lungs or Pleura / Esophageal Cancers / Lung Cancers / Malignant Pleural Mesothelioma (MPM) / Melanoma / Sarcomas / Thoracic Sarcomas / Thorasic Cancers / Thymic Carcinoma1
1, 2TerminatedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2Unknown StatusTreatmentCancer of the Head / Cancer of the Larynx / Cancer of the Neck / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
1, 2Unknown StatusTreatmentHead and Neck Carcinoma1
1, 2WithdrawnTreatmentLiver Cancer1
2Active Not RecruitingTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentEsophageal Cancers1
2Active Not RecruitingTreatmentFallopian Tube Cancer / Peritoneal Cavity Cancer / Recurrent Ovarian Epithelial Cancer1
2Active Not RecruitingTreatmentFamilial Adenomatous Polyposis (FAP)1
2Active Not RecruitingTreatmentNeurofibromatosis 11
2CompletedNot AvailableMetastatic Hormone Refractory Prostate Cancer1
2CompletedDiagnosticNeoplasms1
2CompletedPreventionCancer, Breast2
2CompletedPreventionCervical Cancers / Cervical Carcinoma / Cervical Intraepithelial Neoplasia Grade 2 / Cervical Intraepithelial Neoplasia Grade 2/3 / Cervical Intraepithelial Neoplasia Grade 3 / Stage 0 Cervical Cancer1
2CompletedPreventionColorectal Cancers1
2CompletedPreventionEsophageal Cancers1
2CompletedPreventionHead and Neck Carcinoma1
2CompletedPreventionHead and Neck Carcinoma / Precancerous Conditions1
2CompletedPreventionLung Cancers2
2CompletedPreventionMonoclonal Gammopathy of Undetermined Significance (MGUS) / Multiple Myeloma (MM) / Smoldering Multiple Myeloma (SMM)1
2CompletedPreventionNo Evidence of Disease2
2CompletedPreventionNon-Melanomatous Skin Cancer1
2CompletedPreventionOral Mucositis1
2CompletedPreventionPrecancerous Conditions1
2CompletedSupportive CarePain1
2CompletedSupportive CareTonsillitis1
2CompletedTreatmentAdenotonsillectomy / Postoperative pain / Tonsillectomy1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnaplastic Glioma of Brain / Brain Cancer / Glioblastoma Multiforme (GBM)1
2CompletedTreatmentBenign Prostatic Hyperplasia (BPH)1
2CompletedTreatmentBrain Stem Gliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCarcinoma, Colorectal / Colorectal Adenomas1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentColorectal Cancers4
2CompletedTreatmentDental Pain2
2CompletedTreatmentEsophageal Cancers2
2CompletedTreatmentFacial Pain1
2CompletedTreatmentGastric Carcinoma / Gastroesophageal Junction Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma1
2CompletedTreatmentHead and Neck Carcinoma / Lung Cancers1
2CompletedTreatmentLocally Advanced Rectal Cancer1
2CompletedTreatmentLung Cancers5
2CompletedTreatmentMacular Degeneration1
2CompletedTreatmentMalignant Neoplasm of Pancreas2
2CompletedTreatmentNeoplasms, Breast1
2CompletedTreatmentNon Muscle Invasive Bladder Cancer1
2CompletedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small Cell Lung Cancer Recurrent / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer2
2CompletedTreatmentOsteoarthritis (OA)1
2CompletedTreatmentPain1
2CompletedTreatmentPain, Acute2
2CompletedTreatmentPostoperative pain1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Respiratory Papillomatosis1
2CompletedTreatmentRenal Cell Adenocarcinoma / Stage IV Renal Cell Cancer1
2CompletedTreatmentSarcomas1
2CompletedTreatmentSchizophrenic Disorders1
2CompletedTreatmentTemporomandibular Joint Disorders1
2Not Yet RecruitingTreatmentAnatomic Stage IV Breast Cancer AJCC / Estrogen Receptor Negative / HER2/Neu Negative / Progesterone Receptor Negative / Triple -Negative Breast Cancer1
2Not Yet RecruitingTreatmentKnee Replacement Surgery / Manipulation1
2Not Yet RecruitingTreatmentSpinal Muscular Atrophy (SMA)1
2RecruitingBasic ScienceCarcinoma, Breast1
2RecruitingPreventionOral Squamous Cell Carcinoma1
2RecruitingPreventionPain, Neuropathic1
2RecruitingSupportive CareCancer of the Breast / Cancer, Breast / Malignant Neoplasm of Female Breast1
2RecruitingTreatmentAllodynia / Migraine With Aura / Migraine Without Aura1
2RecruitingTreatmentAnkylosing Spondylitis (AS)1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCarcinoma of Buccal Mucosa / Head and Neck Carcinoma / Oral Squamous Cell Carcinoma / Tongue Cancers1
2RecruitingTreatmentChemotherapy Effect / Malignant Neoplasm of Pancreas1
2RecruitingTreatmentColon Carcinoma1
2RecruitingTreatmentKnee Osteoarthritis (Knee OA)2
2RecruitingTreatmentKnee Replacement Surgery / Postoperative pain1
2RecruitingTreatmentLymphangioleiomyomatosis (LAM)1
2RecruitingTreatmentMedulloblastomas1
2RecruitingTreatmentRecurrent Neuroblastoma1
2RecruitingTreatmentThyroid Eye Disease1
2RecruitingTreatmentTonsillectomy1
2RecruitingTreatmentTumors, Solid1
2TerminatedNot AvailableUterine Cancers1
2TerminatedPreventionCancer, Breast1
2TerminatedPreventionPancreas Neoplasms1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Prostate Cancer1
2TerminatedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentBreast Cancer, Metastatic / Cancer treatment1
2TerminatedTreatmentCancer of the Ovary / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentColorectal Cancers / Familial Adenomatous Polyposis (FAP)1
2TerminatedTreatmentEsophageal Cancers1
2TerminatedTreatmentHead and Neck Carcinoma / Lung Cancers1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentLaryngeal Papilloma1
2TerminatedTreatmentLung Cancers1
2TerminatedTreatmentMetastatic Cancers / Prostate Cancer1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Colorectal1
2TerminatedTreatmentOvarian Carcinoma1
2TerminatedTreatmentProstate Cancer1
2TerminatedTreatmentRecurrent Colon Carcinoma / Recurrent Rectal Carcinoma / Stage IVA Colon Cancer / Stage IVA Rectal Cancer / Stage IVB Colon Cancer / Stage IVB Rectal Cancer1
2TerminatedTreatmentRheumatoid Arthritis1
2Unknown StatusPreventionHead and Neck Carcinoma1
2Unknown StatusSupportive CareKnee Osteoarthritis (Knee OA)1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors2
2Unknown StatusTreatmentColorectal Cancers1
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentLung Cancers2
2Unknown StatusTreatmentProstate Cancer2
2WithdrawnPreventionNon-Melanomatous Skin Cancer1
2WithdrawnTreatmentHigh-Grade Squamous Intraepithelial Lesions / Stage 0 Cervical Cancer1
2WithdrawnTreatmentMetastatic Colorectal Cancers1
2WithdrawnTreatmentPreeclampsia1
2, 3CompletedPreventionDuodenal Neoplasms / Duodenal Polyps / Familial Adenomatous Polyposis (FAP)1
2, 3CompletedPreventionRecurrent Bladder Cancer1
2, 3CompletedTreatmentProstate Cancer1
2, 3RecruitingTreatmentProstate Cancer1
2, 3TerminatedTreatmentOral Cavity Cancer1
2, 3WithdrawnPreventionPrecancerous Conditions1
3Active Not RecruitingTreatmentCancer, Breast1
3Active Not RecruitingTreatmentColorectal Cancers1
3Active Not RecruitingTreatmentLow Back Pain (LBP)1
3CompletedPreventionAlzheimer's Disease (AD)1
3CompletedPreventionMalignant Neoplasm of Colon / Rectal Carcinoma1
3CompletedPreventionPrevention / Smoking1
3CompletedSupportive CareCelebrex / Pelubiprofen / Rheumatoid Arthritis1
3CompletedTreatmentAcute Gouty Arthritis1
3CompletedTreatmentAcute Post-surgical Pain1
3CompletedTreatmentAnkylosing Spondylitis (AS)2
3CompletedTreatmentAnterior Cruciate Ligament Injury1
3CompletedTreatmentArthritis / Bleeding Ulcers1
3CompletedTreatmentArthritis / Cardiovascular Disease (CVD) / Cerebrovascular Disorders1
3CompletedTreatmentArthritis / Gastric Ulcer (GU)1
3CompletedTreatmentColorectal Adenomas1
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentHigh Blood Pressure (Hypertension)2
3CompletedTreatmentKnee Osteoarthritis (Knee OA)6
3CompletedTreatmentLow Back Pain (LBP)2
3CompletedTreatmentMacular Degeneration1
3CompletedTreatmentMetastatic Breast Cancer (MBC)1
3CompletedTreatmentOsteoarthritis (OA)11
3CompletedTreatmentOsteoarthritis (OA) / Pain1
3CompletedTreatmentOsteoarthritis (OA) / Peptic Ulcers1
3CompletedTreatmentOther Acute Postoperative Pain2
3CompletedTreatmentPain1
3CompletedTreatmentPain, Acute1
3CompletedTreatmentPharyngitis1
3CompletedTreatmentPost Operative Pain1
3CompletedTreatmentPostoperative pain1
3CompletedTreatmentRheumatoid Arthritis, Juvenile1
3Not Yet RecruitingTreatmentBipolar Disorder (BD) / Postpartum Depression1
3RecruitingPreventionHysteroscopy2
3RecruitingTreatmentBipolar Disorder (BD) / Depression / Depression, Bipolar / Moods Disorders1
3RecruitingTreatmentInfluenza, Human1
3RecruitingTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis (OA)1
3RecruitingTreatmentLiver Cancer / Postoperative pain1
3RecruitingTreatmentNasopharyngeal Carcinoma1
3RecruitingTreatmentOpioids Use / Shoulder Pain1
3RecruitingTreatmentPain, Acute1
3SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
3SuspendedTreatmentMemory Disorders1
3TerminatedPreventionAdenomatous Polyposis Coli1
3TerminatedPreventionColorectal Cancers1
3TerminatedPreventionOsteoarthritis (OA)1
3TerminatedSupportive CareCancer, Breast / Colorectal Cancers / Pain1
3TerminatedTreatmentLung Cancers1
3Unknown StatusNot AvailableMalignant Neoplasm of Pancreas1
3Unknown StatusTreatmentColon Neoplasms1
3Unknown StatusTreatmentHead and Neck Carcinoma1
3Unknown StatusTreatmentLocalized Primary Osteoarthritis of Hip / Localized Primary Osteoarthritis of Knee1
3Unknown StatusTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
4Active Not RecruitingSupportive CareReverse or Primary Total Shoulder / Rotator Cuff- Full Thickness- Repair1
4CompletedNot AvailableCelecoxib / Function / Minimally Invasive Total Knee Arthroplasty / Pain Management1
4CompletedNot AvailableGastroduodenal Ulcers1
4CompletedBasic ScienceHigh Blood Pressure (Hypertension)1
4CompletedBasic ScienceIschaemic Heart Diseases / Osteoarthritis (OA)1
4CompletedPreventionArthroscopy2
4CompletedPreventionHealthy Volunteers1
4CompletedPreventionOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedPreventionPeptic Ulcers1
4CompletedPreventionPostoperative pain1
4CompletedTreatmentAnalgesics1
4CompletedTreatmentAnkle Sprains1
4CompletedTreatmentAnkylosing Spondylitis (AS) / Inflammatory Reaction1
4CompletedTreatmentBack Pain1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentBowel Diseases, Inflammatory1
4CompletedTreatmentColorectal Cancers1
4CompletedTreatmentColorectal Disorders1
4CompletedTreatmentCoronary Arteriosclerosis1
4CompletedTreatmentCyclooxygenase 2 Inhibitors / Postoperative pain / Thyroidectomy1
4CompletedTreatmentHealthy Volunteers2
4CompletedTreatmentHepatocellular,Carcinoma1
4CompletedTreatmentHypertension and Coronary Artery Disease1
4CompletedTreatmentInflammatory Reaction / Pain1
4CompletedTreatmentKnee Osteoarthritis (Knee OA)7
4CompletedTreatmentKnee Osteoarthritis (Knee OA) / Osteoarthritis, Hip1
4CompletedTreatmentLow Back Pain (LBP)1
4CompletedTreatmentMagnetic Resonance Imaging (MRI) / Spondylarthropathy1
4CompletedTreatmentNarcotic Use / Nausea / Occasional Constipation / Pain1
4CompletedTreatmentOsteoarthritis (OA)2
4CompletedTreatmentOsteoarthritis (OA) / Rheumatoid Arthritis1
4CompletedTreatmentOsteoarthritis, Hip1
4CompletedTreatmentPostoperative Pain Management / Total Knee Arthroplasty (TKA)1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentRheumatoid Arthritis, Juvenile1
4CompletedTreatmentRotator Cuff Syndrome1
4Enrolling by InvitationTreatmentBile Duct Carcinoma / Malignant Neoplasm of Pancreas1
4Enrolling by InvitationTreatmentNonspecific Pain Post Traumatic Injury1
4Not Yet RecruitingPreventionColposcopy1
4Not Yet RecruitingPreventionPain1
4Not Yet RecruitingTreatmentAnkylosing Spondylitis (AS)1
4Not Yet RecruitingTreatmentPharmacokinetics of Celecoxib in Children1
4Not Yet RecruitingTreatmentPostoperative pain1
4Not Yet RecruitingTreatmentPostoperative pain / Renal Stones1
4RecruitingTreatmentAnkylosing Spondylitis (AS)1
4RecruitingTreatmentAnkylosing Spondylitis (AS) / Spondyloarthritis, Axial1
4RecruitingTreatmentKnee Osteoarthritis (Knee OA)1
4RecruitingTreatmentLigament Injury1
4RecruitingTreatmentOsteoarthritis (OA)1
4RecruitingTreatmentOsteoarthritis Hand1
4RecruitingTreatmentPain Management1
4RecruitingTreatmentRheumatoid Arthritis1
4TerminatedNot AvailableFamilial Adenomatous Polyposis (FAP)1
4TerminatedTreatmentChronic Low Back Pain (CLBP)1
4TerminatedTreatmentChronic Low Back Pain With a Neuropathic Component1
4TerminatedTreatmentCrohn's Disease (CD)1
4TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
4TerminatedTreatmentOsteoarthritis (OA) / Pain1
4TerminatedTreatmentPain1
4TerminatedTreatmentUterine Artery Embolization / Uterine Leiomyomas1
4Unknown StatusTreatmentAngioplasty, Transluminal, Percutaneous Coronary / Coronary Artery Restenosis1
4Unknown StatusTreatmentKnee Osteoarthritis (Knee OA)1
4Unknown StatusTreatmentPain1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
4WithdrawnTreatmentPost Operative Pain Control1
4WithdrawnTreatmentUreteral Calculus1
Not AvailableCompletedNot AvailableAnkylosing Spondylitis (AS)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailableOsteoarthritis (OA)1
Not AvailableCompletedNot AvailablePatients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain1
Not AvailableCompletedDiagnosticGonadotropin and Ovarian Hormone Levels (FSH, LH, E2, P) / Menstrual Cycles (Total Length, Bleeding Days) / Ovulation (Follicular Rupture Yes/no)1
Not AvailableCompletedDiagnosticLuteal Development / Ovulation1
Not AvailableCompletedPreventionAlzheimer's Disease (AD) / Dementias1
Not AvailableCompletedScreeningHealthy Volunteers1
Not AvailableCompletedTreatmentAntiphospholipid Antibody Syndrome1
Not AvailableCompletedTreatmentHip Labral Tears1
Not AvailableCompletedTreatmentIntracerebral Hemorrhage1
Not AvailableCompletedTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableCompletedTreatmentLung Cancers1
Not AvailableCompletedTreatmentPain1
Not AvailableCompletedTreatmentSchizophrenic Disorders1
Not AvailableCompletedTreatmentSpinal Stenosis of Lumbar Region1
Not AvailableCompletedTreatmentSquamous Cell Carcinoma (SCC)1
Not AvailableCompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
Not AvailableNot Yet RecruitingPreventionPrevention of Post Operative Ileus1
Not AvailableNot Yet RecruitingTreatmentPulpitis dental1
Not AvailableRecruitingPreventionOssification, Heterotopic1
Not AvailableRecruitingTreatmentDepression / Inflammatory Reaction1
Not AvailableRecruitingTreatmentHip Pain Chronic1
Not AvailableRecruitingTreatmentKnee Osteoarthritis (Knee OA)1
Not AvailableRecruitingTreatmentLow Back Pain (LBP)1
Not AvailableRecruitingTreatmentStiffness Following Total Knee Arthroplasty1
Not AvailableRecruitingTreatmentTreatment Outcomes1
Not AvailableTerminatedNot AvailableOsteoarthritis (OA)1
Not AvailableTerminatedNot AvailableRheumatoid Arthritis, Juvenile1
Not AvailableTerminatedTreatmentColorectal Cancers1
Not AvailableTerminatedTreatmentColorectal Cancers / Malignant Neoplasm of Colon1
Not AvailableTerminatedTreatmentDiabetic Nephropathies1
Not AvailableTerminatedTreatmentPain1
Not AvailableUnknown StatusNot AvailableHip Fractures1
Not AvailableUnknown StatusTreatmentAcute Respiratory Distress Syndrome (ARDS) / Blunt Chest Trauma1
Not AvailableUnknown StatusTreatmentHealthy Volunteers1
Not AvailableUnknown StatusTreatmentPostoperative pain2
Not AvailableWithdrawnPreventionBrca1 Mutation Carrier / Brca2 Mutation Carrier / Cancer of the Ovary1
Not AvailableWithdrawnSupportive CareCachexia / Cancer of the Ovary / Malignant Lymphomas / Melanoma (Skin) / Pain / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableWithdrawnTreatmentBladder Cancers1

Pharmacoeconomics

Manufacturers
  • Gd searle llc
Packagers
  • 4uOrtho LLC
  • Apotheca Inc.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • Cardinal Health
  • Direct Pharmaceuticals Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • GD Searle LLC
  • H.J. Harkins Co. Inc.
  • Innoviant Pharmacy Inc.
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Prepackage Specialists
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Resource Optimization and Innovation LLC
  • Sandhills Packaging Inc.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • Vangard Labs Inc.
Dosage forms
FormRouteStrength
KitOral; Topical
CapsuleOral100 mg
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral100 mg/1
CapsuleOral400 mg/1
CapsuleOral50 mg/1
KitOral
CapsuleOral400 mg
Prices
Unit descriptionCostUnit
Celebrex 400 mg capsule6.78USD capsule
Celebrex 200 mg capsule4.52USD capsule
Celebrex 100 mg capsule2.75USD capsule
Celebrex 50 mg capsule1.26USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5972986No1998-04-142018-04-14Us
CA2267186No2002-05-142017-10-14Canada
CA2177576No1999-10-262014-11-14Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPoorly solublehttps://www.lclabs.com/products/c-1502-celecoxib
logP3.53MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.00503 mg/mLALOGPS
logP3.99ALOGPS
logP4.01ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)10.7ChemAxon
pKa (Strongest Basic)-0.42ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.98 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.23 m3·mol-1ChemAxon
Polarizability35.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateNon-substrate0.9287
P-glycoprotein inhibitor INon-inhibitor0.8619
P-glycoprotein inhibitor IINon-inhibitor0.792
Renal organic cation transporterNon-inhibitor0.8582
CYP450 2C9 substrateNon-substrate0.6237
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5751
CYP450 1A2 substrateInhibitor0.7805
CYP450 2C9 inhibitorInhibitor0.6172
CYP450 2D6 inhibitorNon-inhibitor0.8594
CYP450 2C19 inhibitorInhibitor0.7169
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7392
Ames testNon AMES toxic0.7185
CarcinogenicityNon-carcinogens0.7905
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3719 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9856
hERG inhibition (predictor II)Non-inhibitor0.8419
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-001i-0029000000-1a5ed66ff895eeb127ce
MS/MS Spectrum - , positiveLC-MS/MSsplash10-001i-0129000000-a967b7f9e88a461e3db4
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01q9-2598000000-f71f4f9eb7c83ddf79f4
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-001i-0029000000-13ff69b3abd31dde6bae

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Benzenesulfonamides / Benzenesulfonyl compounds / Toluenes / Organosulfonamides / Heteroaromatic compounds / Aminosulfonyl compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organofluorides
show 3 more
Substituents
Phenylpyrazole / Benzenesulfonamide / Benzenesulfonyl group / Toluene / Monocyclic benzene moiety / Organosulfonic acid amide / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Sulfonyl
show 15 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrazoles, sulfonamide (CHEBI:41423)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology. 2002 Jun;122(7):1913-23. [PubMed:12055598]
  2. Scheiman JM: Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors. Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. [PubMed:12086292]
  3. Reddy BS, Rao CV: Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol. 2002;21(2):155-64. [PubMed:12086402]
  4. Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf. 2002;25(7):537-44. [PubMed:12093311]
  5. Lu S, Zhang X, Badawi AF, El-Sohemy A, Archer MC: Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids. Cancer Lett. 2002 Oct 8;184(1):7-12. [PubMed:12104042]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein serine/threonine kinase activity
Specific Function
Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its targets include: protein kinase B (PKB/AKT1, PKB/AKT2, PKB...
Gene Name
PDPK1
Uniprot ID
O15530
Uniprot Name
3-phosphoinositide-dependent protein kinase 1
Molecular Weight
63151.305 Da
References
  1. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, Fowble JW, Ward PJ, Chen CS: 3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res. 2004 Feb 15;64(4):1444-51. [PubMed:14973075]
  2. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS: From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004 Jun 15;64(12):4309-18. [PubMed:15205346]
  3. Tong Z, Wu X, Ovcharenko D, Zhu J, Chen CS, Kehrer JP: Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005 Oct 15;391(Pt 2):441-8. [PubMed:16060857]
  4. Li J, Zhu J, Melvin WS, Bekaii-Saab TS, Chen CS, Muscarella P: A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth. J Gastrointest Surg. 2006 Feb;10(2):207-14. [PubMed:16455452]
  5. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS: Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3. [PubMed:16887935]
Details
3. Carbonic anhydrase 2
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
Gene Name
CA2
Uniprot ID
P00918
Uniprot Name
Carbonic anhydrase 2
Molecular Weight
29245.895 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Details
4. Carbonic anhydrase 3
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Reversible hydration of carbon dioxide.
Gene Name
CA3
Uniprot ID
P07451
Uniprot Name
Carbonic anhydrase 3
Molecular Weight
29557.215 Da
References
  1. Nishimori I, Minakuchi T, Onishi S, Vullo D, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides. Bioorg Med Chem. 2007 Dec 1;15(23):7229-36. Epub 2007 Aug 25. [PubMed:17826101]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Efflux transmembrane transporter activity
Specific Function
Drug efflux transporter present in a number of stem cells that acts as a regulator of cellular differentiation. Able to mediate efflux from cells of the rhodamine dye and of the therapeutic drug do...
Gene Name
ABCB5
Uniprot ID
Q2M3G0
Uniprot Name
ATP-binding cassette sub-family B member 5
Molecular Weight
138639.48 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A: The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. Mol Cancer. 2013 May 24;12:47. doi: 10.1186/1476-4598-12-47. [PubMed:23705854]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Details
2. Cytochrome P450 2C9
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Davies NM, McLachlan AJ, Day RO, Williams KM: Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet. 2000 Mar;38(3):225-42. [PubMed:10749518]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  3. Mo SL, Zhou ZW, Yang LP, Wei MQ, Zhou SF: New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126. [PubMed:20167001]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  5. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M: Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos. 2001 Apr;29(4 Pt 1):368-74. [PubMed:11259318]
  6. Rodrigues AD: Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75. Epub 2005 Aug 23. [PubMed:16118328]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K: Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther. 2003 Aug;74(2):130-7. [PubMed:12891223]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
May be an organic anion pump relevant to cellular detoxification.
Gene Name
ABCC4
Uniprot ID
O15439
Uniprot Name
Multidrug resistance-associated protein 4
Molecular Weight
149525.33 Da
References
  1. Reid G, Wielinga P, Zelcer N, van der Heijden I, Kuil A, de Haas M, Wijnholds J, Borst P: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. Epub 2003 Jun 30. [PubMed:12835412]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name
ABCB11
Uniprot ID
O95342
Uniprot Name
Bile salt export pump
Molecular Weight
146405.83 Da
References
  1. Pedersen JM, Matsson P, Bergstrom CA, Hoogstraate J, Noren A, LeCluyse EL, Artursson P: Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. doi: 10.1093/toxsci/kft197. Epub 2013 Sep 6. [PubMed:24014644]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:40